CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma

Tim van Mieghem; Vera M. Abeler; Philippe Moerman; Lieve Verbist; Ignace Vergote; Frederic Amant

doi:https://doi.org/10.1016/j.ygyno.2005.06.013

CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma

Tim van Mieghem, Vera M. Abeler, Philippe Moerman, Lieve Verbist, Ignace Vergote, Frederic Amant

Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

: The low incidence of ovarian adenosarcomas explains the paucity of available data regarding their biologic markers. Our aim was to investigate the presence of CD10, estrogen and progesterone receptors (ER and PR) in these tumors. : Four cases of primary ovarian adenosarcoma were retrieved in our pathology databases. We assessed the immunohistochemical stainings for ER, PR and CD10 in 3 ovarian adenosarcomas without sarcomatous overgrowth (OAS), and 1 ovarian adenosarcoma with sarcomatous overgrowth (OAS-S). When considering the malignant stromal component, 2 OAS showed the presence of ER and PR, whereas the OAS-S was only ER positive. CD10 positivity was observed in the sarcomatous cells of all 3 OAS but was absent in the OAS-S. : The identification of a hormone sensitive disease is the main clinical implication of this study. Moreover, the current results add OAS to the list of CD10 positive ovarian tumors

Original language	English
Pages (from-to)	493-496
Journal	Gynecologic Oncology
Volume	99
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2005.06.013
Publication status	Published - 2005

Access to Document

https://doi.org/10.1016/j.ygyno.2005.06.013

Cite this

@article{760079cc726f402aa23d6fe331e6f1c2,

title = "CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma",

abstract = ": The low incidence of ovarian adenosarcomas explains the paucity of available data regarding their biologic markers. Our aim was to investigate the presence of CD10, estrogen and progesterone receptors (ER and PR) in these tumors. : Four cases of primary ovarian adenosarcoma were retrieved in our pathology databases. We assessed the immunohistochemical stainings for ER, PR and CD10 in 3 ovarian adenosarcomas without sarcomatous overgrowth (OAS), and 1 ovarian adenosarcoma with sarcomatous overgrowth (OAS-S). When considering the malignant stromal component, 2 OAS showed the presence of ER and PR, whereas the OAS-S was only ER positive. CD10 positivity was observed in the sarcomatous cells of all 3 OAS but was absent in the OAS-S. : The identification of a hormone sensitive disease is the main clinical implication of this study. Moreover, the current results add OAS to the list of CD10 positive ovarian tumors",

author = "{van Mieghem}, Tim and Abeler, {Vera M.} and Philippe Moerman and Lieve Verbist and Ignace Vergote and Frederic Amant",

year = "2005",

doi = "https://doi.org/10.1016/j.ygyno.2005.06.013",

language = "English",

volume = "99",

pages = "493--496",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma

AU - van Mieghem, Tim

AU - Abeler, Vera M.

AU - Moerman, Philippe

AU - Verbist, Lieve

AU - Vergote, Ignace

AU - Amant, Frederic

PY - 2005

Y1 - 2005

N2 - : The low incidence of ovarian adenosarcomas explains the paucity of available data regarding their biologic markers. Our aim was to investigate the presence of CD10, estrogen and progesterone receptors (ER and PR) in these tumors. : Four cases of primary ovarian adenosarcoma were retrieved in our pathology databases. We assessed the immunohistochemical stainings for ER, PR and CD10 in 3 ovarian adenosarcomas without sarcomatous overgrowth (OAS), and 1 ovarian adenosarcoma with sarcomatous overgrowth (OAS-S). When considering the malignant stromal component, 2 OAS showed the presence of ER and PR, whereas the OAS-S was only ER positive. CD10 positivity was observed in the sarcomatous cells of all 3 OAS but was absent in the OAS-S. : The identification of a hormone sensitive disease is the main clinical implication of this study. Moreover, the current results add OAS to the list of CD10 positive ovarian tumors

AB - : The low incidence of ovarian adenosarcomas explains the paucity of available data regarding their biologic markers. Our aim was to investigate the presence of CD10, estrogen and progesterone receptors (ER and PR) in these tumors. : Four cases of primary ovarian adenosarcoma were retrieved in our pathology databases. We assessed the immunohistochemical stainings for ER, PR and CD10 in 3 ovarian adenosarcomas without sarcomatous overgrowth (OAS), and 1 ovarian adenosarcoma with sarcomatous overgrowth (OAS-S). When considering the malignant stromal component, 2 OAS showed the presence of ER and PR, whereas the OAS-S was only ER positive. CD10 positivity was observed in the sarcomatous cells of all 3 OAS but was absent in the OAS-S. : The identification of a hormone sensitive disease is the main clinical implication of this study. Moreover, the current results add OAS to the list of CD10 positive ovarian tumors

U2 - https://doi.org/10.1016/j.ygyno.2005.06.013

DO - https://doi.org/10.1016/j.ygyno.2005.06.013

M3 - Article

C2 - 16051333

SN - 0090-8258

VL - 99

SP - 493

EP - 496

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -